Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the carbohydrate-based excipient β-cyclodextrin forms a stable inclusion complex with the active ingredient of Minoxicapil®, potentially enhancing its formulation for hair-loss treatment, and in vitro assays suggest improved proliferation of DPC cells, supporting its use in topical treatments.

In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.

This study found hair regrowth in the majority of AA-affected mice and rats treated with diphencyprone, suggesting its potential utility for understanding human alopecia areata and the drug's therapeutic action.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

Deuruxolitinib is generally safe for treating alopecia areata.

This scoping review found that most of the 64 alopecia areata patients treated with upadacitinib in existing reports experienced significant hair regrowth, with mild side effects, but the authors call for larger studies to confirm these outcomes.

This case report describes a 35-year-old male with Type 2 diabetes who experienced scalp hair loss after increasing his dose of Teneligliptin without supervision, which resolved after discontinuing the medication.

This study described a case where both alopecia universalis and Crohn's ileitis in a 23-year-old man showed remarkable improvement with the JAK1 inhibitor upadacitinib, highlighting its potential as a treatment for patients with concurrent conditions.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

In this study, teicoplanin significantly improved hair regrowth and follicle size in mice with dihydrotestosterone-induced androgenetic alopecia, suggesting its potential as a treatment option for hair loss due to its ability to enhance cell proliferation and decrease androgen receptor protein levels.

This study developed dutasteride-loaded microneedle systems using a specific polymer to enhance transdermal delivery, demonstrating efficient drug release and increased accumulation in hair follicles, thus supporting their potential for treating androgenic alopecia.

This study found that JAK1 and JAK2 inhibitors increase β-catenin activity in human hair follicle cells, suggesting an additional therapeutic mechanism for treating severe alopecia areata.

This study found that WD-aptamer increased β-catenin expression and promoted human hair follicle dermal papilla cell proliferation by interfering with the CXXC5-Dvl1 interaction in the Wnt signaling pathway.

This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.

This study found that the cytoplasmic dynein component Dynlt3 is essential for effective melanosome transport and transfer in mouse melanocytes, linking melanosome positioning and acidity to the Wnt/β-catenin signaling pathway.

In this study, itraconazole was reported to effectively alleviate clinical symptoms in patients with recalcitrant Trichophyton rubrum infections, though toenail infections often recurred, indicating the need for further research on long-term efficacy and safety.

This study found that the DOX derivative AD198 more effectively inhibited cell viability and induced apoptosis in canine cancer cell lines K9TCC and K9OSA compared to DOX in vitro.

This study reported that five patients with alopecia areata achieved satisfactory results using 15 mg of Upadacitinib daily after conventional treatments had failed, without experiencing adverse events.

High kallistatin levels in diabetics worsen wound healing by blocking important cell signals.

This article reviews the traditional uses and documented properties of Tridax procumbens in medicine but reports no original research findings, emphasizing its potential therapeutic applications.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

In this study, a combination of terbinafine and mitotane was used to treat a dog with pituitary-dependent hyperadrenocorticism and dermatophytosis, showing regrowth of hair and negative fungal cultures without detectable adverse effects.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

In this study, a single application of a 10 mg/mL deltamethrin-based solution effectively reduced lice infestations by 98% to 100% in treated horses and prevented new infestations for up to a month, without adverse events reported.

Researchers found that diammonium glycyrrhetate at 0.01 μmol/L significantly promotes human hair follicle growth in vitro and increases hair matrix cell activity, potentially through activating the Wnt/β-catenin signaling pathway.

In this multicentric retrospective study, researchers reported that cutaneous adverse events were common among advanced breast cancer patients treated with cyclin-dependent kinase inhibitors (CDK4/6i), generally mild, and manageable with topical treatments, though in some cases, they led to treatment discontinuation.